Friday, June 14, 2013
Immunomedics Inc., of Morris Plains, N.J., said UCB SA, of Brussels, Belgium, reported new data from a Phase IIb open-label extension study of epratuzumab for systemic lupus erythematosus showing no new safety or tolerability signals, plus reduction in disease activity maintained over two years. Secondary outcome data also showed that compared to baseline values, treatment for two years with epratuzumab was associated in lower corticosteroid use.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.